Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor

Kwang Wook Suh, Steven Piantadosi, Hamid A. Yazdi, Drew M. Pardoll, Henry Brem, Michael A. Choti

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background and Objectives: In preclinical studies, tumor cells genetically altered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) can generate systemic antitumor immunity. Clinically relevant immunotherapeutic approaches for the treatment of colorectal cancer should address efficacy within the liver, a common site of metastatic disease. We investigated the effect of irradiated colon cancer cells engineered to produce GM-CSF on protecting from and treating established liver metastases. Methods: Using a model of liver metastasis by intrahepatic injection of CT-26 murine colon carcinoma cells in syngeneic BALB/c mice, GM-CSF-producing irradiated cells were given as an intradermal vaccine either 14 days prior to hepatic challenge or in animals with early established tumor (days 5 and 10). The presence of tumor, tumor volume, and survival were endpoint determinants. Results: Animals receiving GM-CSF-producing vaccination demonstrated significant protection from subsequent hepatic challenge of viable tumor cells, even at the highest challenge doses. In animals with early established tumors, a significant response was seen with prolongation in survival. Conclusions: We conclude that GM-CSF autologous tumor vaccination was effective for the treatment of hepatic colorectal metastases in this murine model. These findings provide support for immunotherapeutic approaches for metastatic liver cancer.

Original languageEnglish (US)
Pages (from-to)218-224
Number of pages7
JournalJournal of Surgical Oncology
Volume72
Issue number4
DOIs
StatePublished - 1999

Fingerprint

Cancer Vaccines
Granulocyte-Macrophage Colony-Stimulating Factor
Colon
Neoplasm Metastasis
Carcinoma
Liver
Neoplasms
Vaccination
Therapeutics
Liver Neoplasms
Tumor Burden
Colonic Neoplasms
Colorectal Neoplasms
Immunity
Vaccines
Injections

Keywords

  • Autologous cancer vaccine
  • Cytokines
  • GM-CSF
  • Liver metastases

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor. / Suh, Kwang Wook; Piantadosi, Steven; Yazdi, Hamid A.; Pardoll, Drew M.; Brem, Henry; Choti, Michael A.

In: Journal of Surgical Oncology, Vol. 72, No. 4, 1999, p. 218-224.

Research output: Contribution to journalArticle

Suh, Kwang Wook ; Piantadosi, Steven ; Yazdi, Hamid A. ; Pardoll, Drew M. ; Brem, Henry ; Choti, Michael A. / Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor. In: Journal of Surgical Oncology. 1999 ; Vol. 72, No. 4. pp. 218-224.
@article{c13146b024f1412388e053bf16e04bab,
title = "Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor",
abstract = "Background and Objectives: In preclinical studies, tumor cells genetically altered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) can generate systemic antitumor immunity. Clinically relevant immunotherapeutic approaches for the treatment of colorectal cancer should address efficacy within the liver, a common site of metastatic disease. We investigated the effect of irradiated colon cancer cells engineered to produce GM-CSF on protecting from and treating established liver metastases. Methods: Using a model of liver metastasis by intrahepatic injection of CT-26 murine colon carcinoma cells in syngeneic BALB/c mice, GM-CSF-producing irradiated cells were given as an intradermal vaccine either 14 days prior to hepatic challenge or in animals with early established tumor (days 5 and 10). The presence of tumor, tumor volume, and survival were endpoint determinants. Results: Animals receiving GM-CSF-producing vaccination demonstrated significant protection from subsequent hepatic challenge of viable tumor cells, even at the highest challenge doses. In animals with early established tumors, a significant response was seen with prolongation in survival. Conclusions: We conclude that GM-CSF autologous tumor vaccination was effective for the treatment of hepatic colorectal metastases in this murine model. These findings provide support for immunotherapeutic approaches for metastatic liver cancer.",
keywords = "Autologous cancer vaccine, Cytokines, GM-CSF, Liver metastases",
author = "Suh, {Kwang Wook} and Steven Piantadosi and Yazdi, {Hamid A.} and Pardoll, {Drew M.} and Henry Brem and Choti, {Michael A.}",
year = "1999",
doi = "10.1002/(SICI)1096-9098(199912)72:4<218::AID-JSO7>3.0.CO;2-N",
language = "English (US)",
volume = "72",
pages = "218--224",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor

AU - Suh, Kwang Wook

AU - Piantadosi, Steven

AU - Yazdi, Hamid A.

AU - Pardoll, Drew M.

AU - Brem, Henry

AU - Choti, Michael A.

PY - 1999

Y1 - 1999

N2 - Background and Objectives: In preclinical studies, tumor cells genetically altered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) can generate systemic antitumor immunity. Clinically relevant immunotherapeutic approaches for the treatment of colorectal cancer should address efficacy within the liver, a common site of metastatic disease. We investigated the effect of irradiated colon cancer cells engineered to produce GM-CSF on protecting from and treating established liver metastases. Methods: Using a model of liver metastasis by intrahepatic injection of CT-26 murine colon carcinoma cells in syngeneic BALB/c mice, GM-CSF-producing irradiated cells were given as an intradermal vaccine either 14 days prior to hepatic challenge or in animals with early established tumor (days 5 and 10). The presence of tumor, tumor volume, and survival were endpoint determinants. Results: Animals receiving GM-CSF-producing vaccination demonstrated significant protection from subsequent hepatic challenge of viable tumor cells, even at the highest challenge doses. In animals with early established tumors, a significant response was seen with prolongation in survival. Conclusions: We conclude that GM-CSF autologous tumor vaccination was effective for the treatment of hepatic colorectal metastases in this murine model. These findings provide support for immunotherapeutic approaches for metastatic liver cancer.

AB - Background and Objectives: In preclinical studies, tumor cells genetically altered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) can generate systemic antitumor immunity. Clinically relevant immunotherapeutic approaches for the treatment of colorectal cancer should address efficacy within the liver, a common site of metastatic disease. We investigated the effect of irradiated colon cancer cells engineered to produce GM-CSF on protecting from and treating established liver metastases. Methods: Using a model of liver metastasis by intrahepatic injection of CT-26 murine colon carcinoma cells in syngeneic BALB/c mice, GM-CSF-producing irradiated cells were given as an intradermal vaccine either 14 days prior to hepatic challenge or in animals with early established tumor (days 5 and 10). The presence of tumor, tumor volume, and survival were endpoint determinants. Results: Animals receiving GM-CSF-producing vaccination demonstrated significant protection from subsequent hepatic challenge of viable tumor cells, even at the highest challenge doses. In animals with early established tumors, a significant response was seen with prolongation in survival. Conclusions: We conclude that GM-CSF autologous tumor vaccination was effective for the treatment of hepatic colorectal metastases in this murine model. These findings provide support for immunotherapeutic approaches for metastatic liver cancer.

KW - Autologous cancer vaccine

KW - Cytokines

KW - GM-CSF

KW - Liver metastases

UR - http://www.scopus.com/inward/record.url?scp=0343920755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343920755&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9098(199912)72:4<218::AID-JSO7>3.0.CO;2-N

DO - 10.1002/(SICI)1096-9098(199912)72:4<218::AID-JSO7>3.0.CO;2-N

M3 - Article

C2 - 10589037

AN - SCOPUS:0343920755

VL - 72

SP - 218

EP - 224

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -